Form 4: DiaMedica Therapeutics CEO John Pauls Acquires Stock Options
SEC Form 4
DiaMedica Therapeutics' CEO, John Pauls, reports acquisition of stock options and direct ownership of common shares.
Summary
- On June 1, 2024, John Pauls, the President and CEO of DiaMedica Therapeutics Inc., acquired stock options to purchase 300,000 common shares at an exercise price of $2.90.
- These options vest with respect to 25% of the underlying common shares on June 1, 2025, and the remaining 75% vest quarterly over the following three years, starting September 1, 2025.
- Pauls also directly owns 68,591 voting common shares, which includes 1,749 shares issuable upon settlement of deferred share units.
- The options expire on May 31, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO acquiring stock options generally indicates confidence, but it's a routine transaction.
Positives
- The CEO's acquisition of stock options could be seen as a positive signal, indicating confidence in the company's future performance.
Industry Context
Executive compensation through stock options is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.
Stakeholder Impact
- The acquisition of stock options by the CEO may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/01/2024 | Date of the stock option grant and earliest transaction. |
| 06/01/2025 | 25% of the stock options vest. |
| 09/01/2025 | Quarterly vesting of the remaining 75% of the stock options begins. |
| 05/31/2034 | Expiration date of the stock options. |
| 06/03/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.